منابع مشابه
Expression of Basophil Activation Markers in Pediatric Asthma
Background: Asthma is very common in children and its diagnosis is based on clinical manifestations, which can be misdiagnosed as other respiratory diseases with similar signs and symptoms. Objective: To analyze the expression of ST2L and CD203c in the diagnosis of pediatric asthma. Methods: Basophils were purified from whole blood samples of patients and healthy controls using Ficol-Paque grad...
متن کاملComorbidities of pediatric asthma: A narrative review
Background: Asthma is one of the most common persistent inflammatory respiratory disorders. Comorbidities are relatively common in asthma. The aim of this review study was to find comorbid disorders in children with asthma. Methods: For the purpose of this review, we searched databases including Scopus, Google scholar, PubMed, SID, Irandoc and up-to-date. Key words for the search included chil...
متن کاملPharmacoeconomics in pediatric asthma.
I n Canada throughout the 1990s, inhaled corticosteroids (ICS) have been the treatment of choice, and we continue to view ICS as the mainstay of treatment for persistent asthma in children, except for those whose disease is so mild that they only require infrequent, as-needed 2-agonist treatment.1 Corticosteroid dosage should continue to be individualized, and the minimum effective dose should ...
متن کاملPediatric Asthma
Asthma is a chronic inflammatory disease of the airways that is characterized by reversible airway obstruction, airway hyperresponsiveness to stimuli, variable airway resistance and flow rates, and transient increases in lung volume. Classic symptoms include cough, wheezing, dyspnea, and chest tightness [1]. Worldwide, asthma prevalence is increasing, with generally higher prevalence rates in w...
متن کاملMontelukast in pediatric asthma management.
UNLABELLED Leukotriene modifiers (receptor antagonist and biosynthesis inhibitor) represent the first mediator specific therapeutic option for asthma. Montelukast, a leukotriene receptor antagonist is the only such agent approved for use in pediatric patients. Montelukast modifies action of leukotrienes, which are the most potent bronchoconstrictors, by blocking Cysteinyl leukotriene receptors....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Pediatrics
سال: 2019
ISSN: 2296-2360
DOI: 10.3389/fped.2019.00289